Background/aims: To determine the serum vascular endothelial growth factor receptor-1 (VEGFR-1) levels in hepatocellular carcinoma patients and its correlations with the clinical and laboratory parameters.
Methodology: Serum VEGFR-1 levels were measured in 18 biopsy-proven treatment-naive hepatocellular carcinoma patients (female/male: 5/13; mean age: 59.22 +/- 13.15 years) and in age- and sex-matched healthy controls. Possible associations were also evaluated between serum VEGFR-1 levels and etiology and severity of chronic liver disease, serum alpha-fetoprotein levels, presence of ascites and portal vein thrombosis, and tumor number, size and stage.
Results: Serum VEGFR-1 levels were undetectable in all healthy subjects, while all of the patients with hepatocellular carcinoma had increased VEGFR-1 (p < 0.001). Serum VEGFR-1 levels did not correlate with the clinical and laboratory parameters and tumor characteristics in hepatocellular carcinoma.
Conclusions: VEGFR-1 is involved in the regulation of carcinogenesis in hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Discovery of a MET-driven monogenic cause of steatotic liver disease.
Hepatology
January 2025
Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
Background Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about a third of adults worldwide and is projected soon to be the leading cause of cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction-associated steatohepatitis (MASH), liver cirrhosis, and hepatocellular carcinoma. MASLD pathogenesis is believed to involve a combination of genetic and environmental risk factors.
View Article and Find Full Text PDFShort-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma.
Hepatology
January 2025
Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China.
Background And Aims: Immune checkpoint inhibitors (ICIs) have revolutionized systemic hepatocellular carcinoma (HCC) treatment. Nevertheless, numerous patients are refractory to ICIs therapy. It is currently unknown whether diet therapies such as short-term starvation (STS) combined with ICIs can be used to treat HCC.
View Article and Find Full Text PDFDosimetry Assessment in Predicting Treatment Outcomes Following Yttrium-90 Transarterial Radioembolization of Hepatic Tumors.
Cancer Biother Radiopharm
January 2025
Department of Interventional Radiology, University of Kansas Medical Center, Kansas City, Kansas, USA.
To evaluate the use of yttrium-90 (Y90) dosimetry in predicting treatment outcomes when used following transarterial radioembolization with SIR-Spheres® (Resin Y90) in patients with hepatic tumors. This single institution retrospective analysis included 100 patients with hepatocellular carcinoma, colorectal carcinoma or other liver metastases who underwent transarterial radioembolization with resin Y90 and had imaging follow-up within one year of treatment. Mean tumor dose and mean dose to nontumor was calculated using voxel-based dosimetry software.
View Article and Find Full Text PDFInotodiol induces hepatocellular carcinoma apoptosis by activation of MAPK/ERK pathway.
PLoS One
January 2025
Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, China.
Hepatocellular carcinoma(HCC) has a high mortality and morbidity rate and seriously jeopardizes human life. Chemicals and chemotherapeutic agents have been experiencing problems such as side effects and drug resistance in the treatment of HCC, which cannot meet the needs of clinical treatment. Therefore, finding novel low-toxicity and high-efficiency anti-hepatocellular carcinoma drugs and exploring their mechanisms of action have become the current problems to be solved in the treatment of HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!